Payment overview · 2025
General Payments
$312.27
5 reported records · 4 companies
Healthcare provider profile · identity verified
Joseph Stephen Campos, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GUAYNABO, PR · NPI 1851317119
Verified facts
What the public records show
CMS Open Payments records show Joseph Stephen Campos, MD received $312.27 in general payments during 2025 across 5 reported records.
ABBVIE INC. accounted for 49.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 631 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 738 records involving 435 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 147 records involving 126 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $153.12 | 49.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $112.75 | 36.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.00 | 8.0% | 1 | 2025 |
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $21.40 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $312.27 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $112.75 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $28.12 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PBG PUERTO RICO LLC | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PBG PUERTO RICO LLC | $21.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 57 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 631 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
631 | 166 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 738 supporting records · 435 recipient NPIs · example record 1228798592 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 23 |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 147 supporting records · 126 recipient NPIs · example record 1228798592 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1052 | 404 |
| Gabapentin | Gabapentin | 1003 | 253 |
| Simvastatin | Simvastatin | 737 | 281 |
| Famotidine | Famotidine | 732 | 189 |
| Omeprazole | Omeprazole | 680 | 179 |
| Synthroid | Levothyroxine Sodium | 631 | 166 |
| Losartan Potassium | Losartan Potassium | 620 | 229 |
| Levothyroxine Sodium | Levothyroxine Sodium | 603 | 176 |
| Amlodipine Besylate | Amlodipine Besylate | 556 | 207 |
| Metformin Hcl | Metformin Hcl | 505 | 188 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 489 | 169 |
| Pantoprazole Sodium | Pantoprazole Sodium | 460 | 122 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 428 | 164 |
| Metoprolol Succinate | Metoprolol Succinate | 423 | 159 |
| Montelukast Sodium | Montelukast Sodium | 355 | 93 |
| Meloxicam | Meloxicam | 327 | 194 |
| Lisinopril | Lisinopril | 312 | 111 |
| Tamsulosin Hcl | Tamsulosin Hcl | 302 | 100 |
| Clonazepam | Clonazepam | 253 | 60 |
| Temazepam | Temazepam | 233 | 65 |
| Fluticasone Propionate | Fluticasone Propionate | 212 | 88 |
| Ezetimibe | Ezetimibe | 155 | 59 |
| Tizanidine Hcl | Tizanidine Hcl | 155 | 114 |
| Glipizide Er | Glipizide | 148 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 145 | 60 |
| Enalapril Maleate | Enalapril Maleate | 141 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 56 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 128 | 28 |
| Azithromycin | Azithromycin | 123 | 115 |
| Glipizide | Glipizide | 122 | 46 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 117 | 19 |
| Alendronate Sodium | Alendronate Sodium | 116 | 54 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 114 | 28 |
| Furosemide | Furosemide | 109 | 50 |
| Eliquis | Apixaban | 100 | 23 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 100 | 23 |
| Glimepiride | Glimepiride | 99 | 35 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 97 | 85 |
| Alprazolam | Alprazolam | 96 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 27 |
| Sertraline Hcl | Sertraline Hcl | 91 | 28 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 87 | 50 |
| Carvedilol | Carvedilol | 86 | 39 |
| Cilostazol | Cilostazol | 86 | 17 |
| Irbesartan | Irbesartan | 86 | 27 |
| Atenolol | Atenolol | 85 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 84 | 78 |
| Trazodone Hcl | Trazodone Hcl | 83 | 23 |
| Diclofenac Potassium | Diclofenac Potassium | 80 | 40 |
| Levofloxacin | Levofloxacin | 80 | 72 |
| Xarelto | Rivaroxaban | 78 | 21 |
| Prednisone | Prednisone | 72 | 61 |
| Candesartan Cilexetil | Candesartan Cilexetil | 70 | 26 |
| Lansoprazole | Lansoprazole | 70 | 18 |
| Gemfibrozil | Gemfibrozil | 69 | 28 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 65 | 25 |
| Donepezil Hcl | Donepezil Hcl | 65 | 27 |
| Pregabalin | Pregabalin | 65 | 29 |
| Allopurinol | Allopurinol | 62 | 16 |
| Memantine Hcl | Memantine Hcl | 61 | 24 |
| Etodolac | Etodolac | 60 | 42 |
| Tramadol Hcl | Tramadol Hcl | 60 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 25 |
| Valsartan | Valsartan | 58 | 19 |
| Jardiance | Empagliflozin | 57 | 19 |
| Synjardy | Empagliflozin/Metformin Hcl | 57 | 15 |
| Nifedipine Er | Nifedipine | 56 | 20 |
| Nabumetone | Nabumetone | 52 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | 17 |
| Farxiga | Dapagliflozin Propanediol | 50 | 18 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 50 | 18 |
| Baclofen | Baclofen | 47 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 18 |
| Meclizine Hcl | Meclizine Hcl | 46 | 23 |
| Finasteride | Finasteride | 45 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 16 |
| Metformin Hcl Er | Metformin Hcl | 43 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 14 |
| Latanoprost | Latanoprost | 40 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 13 |
| Lorazepam | Lorazepam | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 13 |
| Fenofibrate | Fenofibrate | 35 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | 26 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 33 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | 12 |
| Celecoxib | Celecoxib | 30 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 28 | 22 |
| Ramipril | Ramipril | 28 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Lumigan | Bimatoprost | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | 12 |
| Digoxin | Digoxin | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 15 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | 12 |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Galantamine Er | Galantamine Hbr | 20 | suppressed |
| Pentoxifylline | Pentoxifylline | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 18 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 18 | 17 |
| Methylprednisolone | Methylprednisolone | 18 | 15 |
| Naproxen | Naproxen | 18 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Ciclopirox | Ciclopirox | 17 | suppressed |
| Estazolam | Estazolam | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 16 | suppressed |
| Sulindac | Sulindac | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Crestor | Rosuvastatin Calcium | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Singulair | Montelukast Sodium | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $312.27 · 5 records | ABBVIE INC. | JARDIANCE, NURTEC ODT, SYNTHROID, UBRELVY, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error